The P per interaction values for treatment by sex subgroup resulted in significant ( P = 0.044) for the on-statin pool or borderline significant ( P = 0.079) in the statin-intolerant group, suggesting an enhanced response in females compared to males.
The PARAGON-HF trial, which included 4796 patients (51.7% women), showed a trend towards a lower rate of the primary endpoint (a composite of hospitalizations for worsening HF and cardiovascular mortality) among patients treated with ARNI compared to those treated with valsartan, without to achieve a statistically significant difference between the two treatments arms.